Trial Profile
The Retinal Pigment Epithelial Detachment changes in Aged-related macular degeneration treated with Aflibercept, Ranibizumab and Bevacizumab
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 05 Jun 2017 New trial record